Page 412 - Clinical Hematology_ Theory _ Procedures ( PDFDrive )

396 PART 6 ■ Neoplastic Disorders

AML -

BOX 21.4 . I k k m

m . T

m x
Esterase Staining Reactions .

T m j -
NAPHTHOL AS-D CHLOROACETATE ESTERASE

POSITIVE REACTIONS* k m m q

P m . R m m

M % m

M m m mm

B m .
S m m

NEGATIVE REACTIONS (B x . ). C m (

M ( ) MDR1 ) x m m-

M ( m ) m k P- . T m

P m m † k m ( . ., )

m m m , x -
ALPHA-NAPHTHYL ESTERASE (PH 7.6)

POSITIVE REACTIONS MDR1 -

M m m

H .

S m ( ) O m m

M m ( ) chemotherapy m

M k MRP, m - –

E ; m-
x; LRP, .

NEGATIVE REACTION (WITH SODIUM FLUORIDE A m -

IINCUBATION) m AML m

M k ,

. P III m
*R m m m .

† O k . P- ( . ., )
.

TABLE 21.13 New er Agents in Development for Treatment of AML

Drug Class Drug Actions

Epigenetic modi ers Hypomethylating agents, IDH1 inhibitor, IDH2 inhibitor, bromodomain inhibitors,

LSD1 inhibitor, histone deacetylase inhibitors

Tyrosine kinase inhibitors FL3 inhibitors ( rst and second generation), KIT inhibitors

Cell-cycle and signaling inhibitors MDM2 inhibitor, PLK inhibitor, aurora kinase inhibitors, cyclin-dependent

kinase inhibitors, phosphatidylinositol 3-kinase inhibitor, PIM kinase inhibitor,

Hedgehog-pathway inhibitors, mTor inhibitors

Nuclear export inhibitor XPO 1 (also called CRM1 inhibitor)

Antibody-based therapies Antibody-drug conjugates, bispeci c antibodies, stem-cell targeting, CXCR4

targeting, immune checkpoint blockade, chimeric antigen receptor T cells

Cytotoxic agents Quinolone derivative, new drug formulation CPX-351, nucleoside analogues

Other agents B-cell CLL-lymphoma 2 protein inhibitor, immunomodulatory drug for example,

lenalidomide, aminopeptidase inhibitor, retinoic acid, CXCR4 antagonist, E-selectin

antagonist, homoharringtonine derivative

Modi ed from Döhner H, Weisdorf DJ, Bloom eld CD. Acute myeloid leukemia, N Engl J Med, 12(373):1148–1149, 2015.